Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
26.22 EUR | +1.20% | -1.06% | +0.46% |
31/05 | Sector Update: Health Care Stocks Higher Late Afternoon | MT |
31/05 | Sector Update: Health Care Stocks Advance Friday Afternoon | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's profit outlook over the next few years is a strong asset.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's high margin levels account for strong profits.
- This company will be of major interest to investors in search of a high dividend stock.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- One of the major weak points of the company is its financial situation.
- The company's enterprise value to sales, at 3.66 times its current sales, is high.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+0.46% | 162B | - | ||
+40.73% | 739B | C+ | ||
+32.83% | 598B | B | ||
-6.30% | 353B | C+ | ||
+15.15% | 318B | B- | ||
+4.05% | 285B | C+ | ||
+15.00% | 240B | B+ | ||
-5.52% | 206B | A+ | ||
+6.17% | 164B | C+ | ||
-.--% | 122B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- PFE Stock
- PFE Stock
- Ratings Pfizer, Inc.